GAITHERSBURG, Md., Aug. 22 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) announced that its Chief Scientific Officer, Gregory Glenn, M.D., will present data on the company’s patch-based, needle-free vaccines for seasonal and avian influenza and travelers’ diarrhea at the “Novel Vaccines: Bridging Research, Development, and Production” conference being held today in Cambridge, Mass.
Dr. Glenn will speak at 9:35 a.m. during the session on “Promising Developments.” His talk will focus on the development of Iomai’s novel TCI (transcutaneous immunization) patch, the company’s Phase 2 clinical programs and pre-clinical activities designed to meet the worldwide call for greater supplies of pandemic flu vaccine.
Dr. Glenn, the founder of Iomai, developed the company’s proprietary TCI technology. This needle-free technology uses a patch placed on the surface of the skin to deliver vaccines and adjuvants via a group of antigen-presenting cells in the skin (Langerhans cells) to the nearby lymph nodes to produce a sustained immune response. Multiple benefits of the patch technology include needle-free administration and the ability to deliver vaccines that could not effectively be delivered using a traditional intramuscular (IM) injection.
The conference is being held at the Royal Sonesta Hotel.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com.
Some matters discussed in this press release constitute “forward-looking statements” that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about Iomai’s ability to stimulate stronger immune responses, the ability of Iomai’s patches to expand the supply of pandemic flu vaccine and otherwise expand vaccine markets, and the benefits of its patch technology. Applicable risks and uncertainties include, among others, that results in future Phase 2 and Phase 3 trials may not replicate results seen in the trials described in this press release; that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates for travelers’ diarrhea or pandemic flu; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading “Risk Factors: in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company’s filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
These statements speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.
Source: Iomai Corporation
